Open Label Extension Study of AMX0035 in Patients With ALS

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DRUG

AMX0035

Combination therapy of PB and TURSO

Trial Locations (24)

19107

The Penn Comprehensive Neuroscience Center, Philadelphia

19140

Temple University Hospital, Philadelphia

21205

Johns Hopkins Hospital, Baltimore

27157

Wake Forest School of Medicine, Winston-Salem

30322

Emory University Hospital, Atlanta

32610

University of Florida College of Medicine, Gainesville

33612

University of South Florida College of Medicine, Tampa

40536

University of Kentucky Medical Center, Lexington

43221

The Ohio State University, Wexner Medical Center, Columbus

48109

University of Michigan, Michigan Medicine, Ann Arbor

52242

University of Iowa, Carver College of Medicine, Iowa City

55415

Hennepin County Medical Center, Minneapolis

63110

Washington University Medical Center, St Louis

68506

Neurology Associates, PC, Lincoln

70121

Ochsner Neuroscience Institute, New Orleans

75214

Texas Neurology, PA, Dallas

78229

University of Texas Health Science Center, San Antonio, San Antonio

85013

Barrow Neurological Institute-Dignity Health, St Joseph's Hospital and Medical Center, Phoenix

92868

University of California, Irvine, Orange

94114

California Pacific Medical Center, San Francisco

97239

Oregon Health & Science University, Portland

98122

Swedish Neuroscience Center, Seattle

02114

Massachusetts General Hospital, Boston

01655

University of Massachusetts Memorial Medical Center, Worcester

Sponsors
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

lead

Amylyx Pharmaceuticals Inc.

INDUSTRY